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Abstract: Prophylactic administration of unfractionated heparin is a common practice in 
a perioperative period. Heparin monitoring with subcutaneous dosing is not recommended; 
however it becomes important in selected patients. We report a case of massive hemorrhage with 
subcutaneous heparin administration in an HIV-positive male patient with cachexia and mild liver 
dysfunction. Prolonged activated plasma thromboplastin time and thrombin time, but normal 
reptilase time well as response to protamine sulfate point towards the heparin effect. Inhibitor 
screen was negative and factor VIII activity was normal. All these rule out the possibility of 
acquired factor VIII inhibitor or any other inhibitor and conﬁ  rm that this bleeding was due to 
heparin overdose. We believe that delayed clearance of UH secondary to possible involvement 
of reticuloendothelial system might have been be responsible for heparin overdose even though 
inadvertent administration of large dose of heparin intravenously can not be completely ruled 
out. Administration of unfractionated heparin to a patient with cachexia and abnormal liver 
function warrants close attention to heparin monitoring or switch to low molecular weight 
heparin since its mechanism of elimination differs.
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Introduction
In critically ill patients, venous thromboembolism (VTE) prophylaxis has been included 
in the bundle of measures designed to prevent the development of complications in 
ventilated patients and became a core indicator of the quality of intensive care.1 Either 
low-dose unfractionated heparin (UH) or low molecular weight heparin (LMWH) is 
regularly used for prophylaxis. We report a life-threatening hemorrhage with UH in an 
human immunodeﬁ  ciency virus (HIV)-positive patient with mild liver impairment.
Case report
A 48-year-old male patient (body mass index [BMI] 21.5 kg/m2) with a history of 
HIV infection, bipolar disorder, metastatic bladder cancer, and persistent pleural 
effusion with left lower lobe collapse was admitted to the surgical intensive care unit 
(SICU) after a left video assisted thoracoscopy and pleurodesis. Surgery was smooth 
and bleeding was minimal. Preoperative medication consisted of abacavir, tenofovir, 
lopinavir-ritonavir, bupropion, divalproex, olanzapin, citalopram and pantoprazole. 
Prior to surgery the patient had elevated serum transaminases (ALT 49 IU/L, AST 
169 IU/L), and bilirubins (total bilirubin 2.2 mg/dL and direct bilirubin 1.8 mg/dL), 
serum albumin was 1.5 g/dL, creatinine was 0.7 mg/dL and serum electrolytes 
were normal. Coagulation tests were elevated, activated partial thromboplastin 
time (PTT) more than prothrombin time (PT) (Table 1). On admission to the SICU 
patient was intubated and mechanically ventilated, two chest tubes were on suction. 
VTE prophylaxis was initiated with the UH at a regimen of 5,000 units twice a day 
subcutaneously. Postoperative course was complicated by rapid atrial ﬁ  brillation 
which responded to cardioversion. Patient was weaned off the ventilator and extubated Therapeutics and Clinical Risk Management 2009:5 52
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within 24 hours. The next day chest tubes were disconnected 
from an active suction and placed to the underwater seal. 
PTT, hematocrit and platelet count were checked on a daily 
basis. PTT climbed slightly during his SICU stay with the 
value of 52.6 s shortly prior to discharge. Patient remained 
hemodynamically stable, there was no output from the chest 
tubes and chest X-ray did not show any signiﬁ  cant ﬂ  uid accu-
mulation. He was transferred from the SICU to the regular 
ﬂ  oor on the postoperative day (POD) 3. On the POD 5 patient 
was readmitted to the SICU because of massive hemorrhage 
from the left hemithorax, up to 900 mL/hour. Prior to immedi-
ate resuscitation with blood products, blood sample was sent 
for coagulation evaluation, cell blood count, blood smear, 
lactate dehydrogenase and haptoglobin (Table 1) and heparin 
was discontinued. Patient was given a recombinant activated 
factor VII (rFVIIa) at a dose of 40 µg/kg as a rescue therapy 
for massive hemorrhage. Prolonged PTT of 150 s as well 
as thrombin time (TT) of 124 s raised suspicion of heparin 
effect. Protamine sulfate was given intravenously at a dose 
of 100 mg and resulted in normalization of TT and shorten-
ing of PTT to a patient’s baseline value (Table 1). Bleeding 
decreased signiﬁ  cantly; however did not stop at the time of 
initial intervention and required continued resuscitation with 
blood products. Within 12 hours hemorrhage subsided. The 
total chest tubes output reached 4360 mL of blood. Patient 
received 10 units of packed red blood cells (PRBC), 6 units 
of fresh frozen plasma (FFP), 15 units of cryoprecipitate. 
Results of additional coagulation tests (reptilase time [RT], 
circulating inhibitors, and levels of factors VIII, IX, XI, and 
XII) became gradually available and are shown in Table 2.
The rest of the ICU stay was uneventful. One of the chest 
tubes could be removed on the POD 8, the other one was 
clamped and patient was transferred to the standard ﬂ  oor in 
a good condition.
Discussion
All patients admitted to the SICU are at risk of developing 
VTE. The risk varies with the type of surgery; however other 
factors like age, coexistent malignancy, infection, mechanical 
ventilation, and paralysis play an important role in the thrombus 
formation. Deep venous thrombosis prophylaxis is necessary 
in all seriously ill and especially in those with HIV infection. 
The literature suggests that hematological abnormalities are 
common in HIV-positive patients.2,3 Many of them develop 
a hypercoagulable state secondary to production of antiphos-
pholipid antibodies, lupus anticoagulant antibodies, and 
increased levels of von Willebrand factor. Others might acquire 
deﬁ  ciencies of protein C, protein S, antithrombin, and heparin 
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cofactor II (HC) during the course of their disease.2,4 Treatment 
with protease inhibitors like ritonavir has been reported as a 
cause of thrombosis in this group of patients as well.2
Our patient presented to the SICU with several risk 
factors of VTE: surgery, mechanical ventilation, history of 
malignancy and HIV status. He was started on UH at a dose 
of 5,000 units twice a day. On POD 5 he developed massive 
hemorrhage from the operated hemithorax. The most notice-
able from coagulation tests was signiﬁ  cantly prolonged PTT. 
This test is used to assess intrinsic and common pathway of 
clot formation. PTT evaluates following factors: ﬁ  brinogen, 
prothrombin, V, VIII, IX, X, XI, and XII. Inadequate quantity 
of any of these factors results in prolongation of PTT. Factors 
deﬁ  ciency can arise from insufﬁ  cient synthesis as in liver 
disease, consumption as in consumptive coagulopathy, or 
inactivation either by circulating inhibitors or through an 
action of heparins. Based on those facts, our differential 
diagnosis included heparin overdose, acquired factors deﬁ  -
ciencies, presence of circulating inhibitors, and disseminated 
intravascular coagulopathy (DIC).
A battery of laboratory tests was done at time of the event 
but only some were readily available. Heparin overdose was 
suspected from prolonged PTT and TT. Protamine sulfate 
was given intravenously and resulted in normalization of TT 
and return of PTT to the baseline. RT and TT measure ﬁ  brino-
gen conversion to ﬁ  brin and are prolonged with low levels 
of ﬁ  brinogen, qualitatively abnormal ﬁ  brinogens, or in pres-
ence of ﬁ  brin/ﬁ  brinogen degradation products. The thrombin 
time, but not the reptilase time, is prolonged in the presence 
of heparin. RT was normal and reinforced our suspicion of 
heparin effect. Heparin levels were checked more than twelve 
hours after the onset of hemorrhage, discontinuation of UH, 
and after protamine sulfate administration. A level of less 
than 0.5 U/mL was detected (therapeutic goal 0.3–0.5 U/mL) 
and indicated the presence of heparin.
It is not uncommon that patients with a history of HIV 
(especially those with hemophilia A or B) develop inhibitors 
to factors VIII or IX during the course of their disease.5,6 
Mixing studies were performed to rule our circulating 
inhibitors. Inhibitors were not detected. Assays for factors 
VIII, IX, XI, and XII were also done and found normal levels 
of measured factors (Table 2).
DIC, a process known to complicate certain pathologies 
including underlying malignancy and liver dysfunction, 
might manifest as a life-threatening hemorrhage and 
was considered in this patient as well. Laboratory tests 
such as low platelets, low ﬁ  brinogen, presence of ﬁ  brin 
degradation products (FDP) or D-dimer and occurrence of 
schistocytes in peripheral blood smear are used to conﬁ  rm 
this predominantly clinical diagnosis.7 Laboratory results 
were inconclusive with mild drop in platelet count (nadir 
of 104 K/uL), normal ﬁ  brinogen (not a sensitive indicator 
since it is an acute phase protein), moderately elevated 
FDP and occasional schistocytes in peripheral blood smear 
(Table 1). Bleeding did not resemble oozing from puncture 
sites as frequently seen with DIC even though its clinical 
presentation frequently varies. Most importantly, we did not 
interfere with the underlying pathology as recommended in 
DIC to correct coagulopathy.
A drop in platelet count made us to consider bleeding 
secondary to heparin-induced thrombocytopenia. Blood 
was examined for heparin-induced antibodies and the test 
was negative.
The heparin overdose remained the most likely expla-
nation for bleeding in our patient. We carefully analyzed 
possible triggering events. There was a certain chance of inad-
vertent administration of large dose of UH intravenously. We 
excluded extensive heparin ﬂ  ush as a cause of UH overdose 
since plain saline ﬂ  ush is used for central venous catheters and 
arterial lines in all our patients. Patient received nine doses of 
UFH prior to readmission to the SICU. Probability that one 
of the doses was given accidentally intravenously instead of 
subcutaneously is not negligible even though only subcutane-
ous administration was documented. Administration of UH 
from a vial with different concentration than 5,000 units/cc is 
certainly a possibility to consider especially after the patient 
was transferred to a regular surgical ward.
We explored other potential causes of heparin effect in 
this patient and concluded that the most probable explanation 
for bleeding would be delayed elimination of UH. After 
parenteral injection UH is removed via two mechanisms, 
saturable and non-saturable which operate in conjunction 
with each other.8 Reticuloendothelial system (RES) and 
endothelial cells represent the saturable mechanism while 
Table 2 Complementary coagulation tests
Reptilase time
(13.5–19.5 sec)
Inhibitors screen Factor VIII
(50%–150%)
Factor IX
(50%–150%)
Factor XI
(50%–150%)
Factor XII
(40%–150%)
17.7 NEG 62 89 60 57Therapeutics and Clinical Risk Management 2009:5 54
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renal elimination stands for nonsaturable or linear removal 
mechanism.8 Lower doses of UH are cleared by RES whereas 
kidneys are responsible for clearance of LMWH and higher 
doses of UH.8 The blockage of the phagocytic capacity of 
RES may prolong the half-life of UH signiﬁ  cantly.8 Multiple 
conditions may cause RES compromise in HIV-infected 
individual, such as viral infection of monocytes or mac-
rophages, effect of antiretroviral therapy with subsequent 
lipodysthrophy or simply liver steatosis from malnutrition. 
We believe that it was the delayed clearance of heparin which 
contributed signiﬁ  cantly to bleeding in our patient. Fragility 
of vessel walls in this profoundly malnourished cachectic 
patient might have played a role as well.
The purpose of our report is to caution about the 
possibility of major hemorrhage with low dose of UH and 
not to discourage VTE prophylaxis. There are multiple stud-
ies evaluating and comparing safety of UH and LMWH and 
only two are being mentioned here. Freedman et al performed 
a meta-analysis of thromboembolic prophylaxis after total 
hip arthroplasty. Fifty-two studies with total 10,929 patients 
were included in the analysis. The authors compared the 
incidence of major wound bleeding and nonmajor wound 
bleeding (gastrointestinal, retroperitoneal, intracerebral, and 
epidural hematoma) with the use of various anticoagulants 
and placebo. The risk of total major bleeding was 3.46% 
with UH 2.2% with LMWH, and 0.56% with placebo and 
the difference was statistically signiﬁ  cant (p  0.0001).9 
A recent review by Crowther and Warkentin quotes several 
meta-analyses and pooled analyses and concludes that major 
bleeding is uncommon with LMWH and UH, bleeding is less 
common when agents are given in prophylactic rather than 
therapeutic doses, and bleeding risk may vary with clinical 
circumstances.10 We believe that both agents have a good 
safety proﬁ  le if appropriately used, pharmacokinetics of 
agents is considered, and the effect is monitored.
Conclusion
Prophylactic subcutaneous administration of UH might 
be complicated by a massive hemorrhage in a patient with 
multiple comorbidities, especially in an HIV-infected indi-
vidual with preoperatively compromised liver function and 
cachexia. DVT prophylaxis with LMWH would be prefer-
able since clearance of LMWH by saturable mechanism is 
negligible.8
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